You just read:

Ivantis Announces Groundbreaking 3 Year Results from FDA Clinical Trial; First Device in Minimally Invasive Glaucoma Surgical (MIGS) Category to Demonstrate Significant Long Term Reduction of Severe Major Surgeries for Glaucoma Patients

News provided by

Ivantis, Inc.

May 02, 2019, 09:03 ET